Article Sidebar

PDF (Tiếng Việt)
Published: 2022-11-29
Abstract Views: 281
Views PDF (Tiếng Việt): 316
DOI: https://doi.org/10.52852/tcncyh.v159i11.1289
Issue
Vol. 159 No. 11 (2022)
Section
Các bài báo
How to Cite
Huy, T. L. ., & Anh, T. Đình . (2022). 22. Treatment result of first-line afatinib for advanced egfr-mutant non-small cell lung cancer in Hanoi Medical University Hospital. Journal of Medical Research, 159(11), 178-186. https://doi.org/10.52852/tcncyh.v159i11.1289

22. Treatment result of first-line afatinib for advanced egfr-mutant non-small cell lung cancer in Hanoi Medical University Hospital

Trinh Le Huy, Tran Dinh Anh

Main Article Content

Abstract

This is a retrospective descriptive study with longitudinal follow-up aimed to assess the efficacy of first-line afatinib treatment in patients with stage IIIC, IV NSCLC with EGFR mutations. The patients were treated at the Department of Oncology and Palliative care, Hanoi Medical University Hospital from January 2018 to June 2021. In 34 patients enrolled in the study, the rate of Del19 and L585R mutations was 44.1% and 20.6%, respectively. The remaining cases were rare mutations or compound mutations. At the time of 8 - 12 weeks, the overall response rate to afatinib reached 76.5%, the stable disease status accounted for 20.6%, and only 2.9% of the cases progressed. The median progression-free survival (PFS) was 12.0 months (5.9 - 18.0 months). There was no statistically significant difference in progression-free survival in exploratory analysis of factors associated with survival. The most common side effects were skin rash (35.3%), paronychia (35.3%), and diarrhea (32.4%). No patient reported grade 4 toxicity or discontinued treatment due to afatinib's toxicity.

Article Details

Keywords

Advanced Non-small cell lung cancer (NSCLC), EGFR mutation, afatinib

References

1. Sung H, Ferlay J, Siegel RL. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660.
2. Thuan Tran Van, APT, Tu Dao Van et al. Cancer control in Vietnam: where are we now. Cancer Control. 2016; 99-104.
3. Planchard D, Popat S, Kerr K, et al. ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275.
4. Wu Y-L, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3.
5. Wu YL, Zhou C, Hu CP, et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1.
6. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31: 3327-34.
7. Park K, Tan EH, O’Byrne K, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806.
8. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8.
9. Watanabe S, Minegishi Y, Yoshizawa H, et al. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014;9(2):189-94. doi: 10.1097/JTO.0000000000000048.
10. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 ;16(7):830-8. doi: 10.1016/S1470-2045(15)00026-1.
11. Kim Y, Lee SH, Ahn JS, et al. Efficacy and Safety of Afatinib for EGFR-mutant Non - small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. Cancer Res Treat. 2019;51(2):502-509. doi: 10.4143/crt.2018.117.
12. Yang JC-H, Schuler M, Popat S, et al. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020;15(5):803-815. doi: 10.1016/j.jtho.2019.12.126.
13. Wu JY, Yu CJ, Chang YC, et al. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011; 17: 3812-21. https://doi.org/10.1158/1078-0432.CCR-10-3408.
15. Yang JC, Sequist LV, Zhou C, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 2016;27(11):2103-2110. doi: 10.1093/annonc/mdw322.
15. Schuler M, Tan EH, O’Byrne K, et al. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol. 2019;145(6):1569-1579. doi: 10.1007/s00432-019-02862-x.